CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to develop a novel oral medication strategy for treating retinal diseases, such as age-related macular degeneration and diabetic retinopathy. By targeting therapeutic molecules directly to the eye, it seeks to enhance treatment efficacy, reduce side effects, and improve patient access to care.
Retinopathies constitute an extreme societal and socioeconomic burden that is expected to increase with an aging population and the increased prevalence of diabetes.
These diseases, including age-related macular degeneration and proliferative diabetic retinopathy share neovascularization as a common etiology involving the pathological growth of retinal capillaries leading to blindness if left untreated.
Current treatment modalities involve specialized injections into the eye that require not onl…
EXPERIMENTICA OY
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Lithuania, Vilnius
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Hungary, VESZPREM
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Hungary, Budapest
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Czechia, PRAGUE
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
